Alvotech Entered into an Exclusive Agreement with Polifarma to Commercialize AVT06, a Proposed Biosimilar to Eylea (aflibercept) in Turkey
Shots:
- Under the terms of the agreement, Alvotech will lead the development and manufacture while Polifarma will be responsible for the market registration and commercialization
- The partnership aims to increase patient access to affordable biologics & also allows Polifarma to diversify its portfolio and strengthen its position in the ophthalmology area
- AVT06, a recombinant fusion protein, and a biosimilar candidate is currently being studied in clinical development. The company initiated a patient study in July 2022 to evaluate the efficacy, safety, and immunogenicity of AVT06 vs Eylea for adult patients with neovascular (wet) age-related macular degeneration
Ref: Alvotech | Image: Alvotech
Related News:- Alvotech Initiates (ALVOEYE) Clinical Study of AVT06, a Proposed Biosimilar to Eylea for Eye Disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
